Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.30 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7765793 | 1.00 | HCAR2 (0.39) | HCAR2KEAP1NFE2L2ALDH1A1TRPA1 | |
| SCHEMBL14814141 | 1.00 | HCAR2 (0.39) | HCAR2KEAP1NFE2L2ALDH1A1TRPA1 | |
| SCHEMBL8844392 | 0.83 | HCAR2 (0.36) | HCAR2KEAP1NFE2L2 | |
| SCHEMBL8844401 | 0.83 | HCAR2 (0.36) | HCAR2KEAP1NFE2L2 | |
| SCHEMBL8842466 | 0.83 | TSHR (0.41) | HCAR2ALDH1A1TRPA1TET2EGLN1 | |
| SCHEMBL8842470 | 0.83 | TSHR (0.41) | HCAR2ALDH1A1TRPA1TET2EGLN1 | |
| SCHEMBL9304844 | 0.80 | HCAR2 (0.40) | HCAR2KEAP1NFE2L2ALDH1A1TET2 | |
| SCHEMBL10430503 | 0.80 | HCAR2 (0.40) | HCAR2KEAP1NFE2L2ALDH1A1TET2 | |
| SCHEMBL7774759 | 0.80 | HCAR2 (0.40) | HCAR2KEAP1NFE2L2ALDH1A1TET2 | |
| SCHEMBL3888280 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-7165786-A | — | — | None | — | — | JP | disclosed |
| EP-4704830-A2 | MRGPRX2 INHIBITORS AND METHODS OF USE THEREOF | Septerna, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4656638-A2 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Japan Tobacco Inc. (JP) | 2025-12-03 | — | — | EP | disclosed |
| WO-2024226914-A2 | MRGPRX2 ANTAGONISTS AND METHODS OF USE THEREOF | SEPTERNA, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20230348438-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-11-02 | — | — | US | disclosed |
| US-20230348438-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-11-02 | — | — | US | disclosed |
| US-20230348438-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-11-02 | — | — | US | disclosed |
| CN-115697327-A | 5-oxo-pyrrolidine-3-carboxamides as NAV1.8 inhibitors | 默沙东有限责任公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20200317644-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2020-10-08 | — | — | US | disclosed |
| EP-3524599-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Japan Tobacco Inc. (JP) | 2019-08-14 | — | — | EP | disclosed |
| US-20130085132-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2013-04-04 | — | — | US | disclosed |
| WO-2013031922-A1 | PYRAZOLE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | 日本たばこ産業株式会社 (JP) | 2013-03-07 | — | — | WO | disclosed |
| EP-0639566-B1 | CYCLIC COMPOUND | SANTEN PHARMACEUTICAL CO LTD (JP) | 2001-06-20 | — | — | EP | disclosed |
| EP-0703919-B1 | PHOSPHOSUCCINIC ACID DERIVATIVES AND THEIR USE AS MEDICAMENTS | BOEHRINGER MANNHEIM GMBH (DE) | 1998-09-02 | — | — | EP | disclosed |
| EP-0618920-B1 | NOVEL PHOSPHONO-SUCCINIC ACID DERIVATIVES, PROCESS FOR PRODUCING THEM AND MEDICAMENTS CONTAINING THESE COMPOUNDS | BOEHRINGER MANNHEIM GMBH (DE) | 1996-08-14 | — | — | EP | disclosed |
| US-5461158-A | Immunodeficiency and autoimmune diseases | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1995-10-24 | — | — | US | disclosed |
| JP-H07165786-A | URIDINES SUBSTITUTED AT 5-POSITION, ITS PRODUCTION AND USE THEREOF | SAWAI HIROAKI | 1995-06-27 | — | — | JP | disclosed |
| EP-0639566-A1 | CYCLIC COMPOUND | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1995-02-22 | — | — | EP | disclosed |
| EP-0618920-A1 | NOVEL PHOSPHONO-SUCCINIC ACID DERIVATIVES, PROCESS FOR PRODUCING THEM AND MEDICAMENTS CONTAINING THESE COMPOUNDS. | BOEHRINGER MANNHEIM GMBH (DE) | 1994-10-12 | — | — | EP | disclosed |
| WO-1993012122-A1 | NOVEL PHOSPHONO-SUCCINIC ACID DERIVATIVES, PROCESS FOR PRODUCING THEM AND MEDICAMENTS CONTAINING THESE COMPOUNDS | BOEHRINGER MANNHEIM GMBH (DE) | 1993-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348438-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | CYP2C19, CYP3A7, CYP3A5 | HCAR2 4076/4885KEAP1 4301/4885NFE2L2 4578/4885 |
| US-20130085132-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | SLC5A1, SLC5A2, SLC34A1 | HCAR2 1836/4885KEAP1 2344/4885NFE2L2 3584/4885 |
| US-20200317644-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | CYP2C19, CYP3A7, CYP3A5 | HCAR2 4076/4885KEAP1 4301/4885NFE2L2 4578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.